A specific antidote for dabigatran: functional and structural characterization
about
Reversal agents for NOACs: Connecting the dotsHow we treat bleeding associated with direct oral anticoagulantsReversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumabConsiderations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant eraManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation TherapyNovel oral anticoagulants and the 73rd anniversary of historical warfarinHemostatic management of patients undergoing ear-nose-throat surgeryNovel antidotes for target specific oral anticoagulantsDifferential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatranNovel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative ManagementThe use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryRole of prothrombin complex concentrate in perioperative coagulation therapyNew oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectivenessReversal of target-specific oral anticoagulantsSafety of new oral anticoagulant drugs: a perspectiveThe European guideline on management of major bleeding and coagulopathy following trauma: fourth editionNew Oral Anticoagulants in Nonvalvular Atrial FibrillationSpotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatranPulmonary embolism: new treatments for an old problemThe current approach of atrial fibrillation managementNon-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewRecent advances in the development of specific antidotes for target-specific oral anticoagulantsThe Reversal of Direct Oral Anticoagulants in Animal Models.Thrombocytopenia induced by dabigatran: two case reportsProthrombin Complex Concentrates for Bleeding in the Perioperative Setting.Outcome of intracerebral hemorrhage associated with different oral anticoagulants.Perioperative management of patients on direct oral anticoagulants.Management of anticoagulant-related intracranial hemorrhage: an evidence-based review.Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillationEvolving use of new oral anticoagulants for treatment of venous thromboembolismUse of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.Management of acute stroke in patients taking novel oral anticoagulants.Expanding use of new oral anticoagulantsMeta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism.Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin timeDecision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation.Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012
P2860
Q26740248-8942A3C1-15D5-4675-8470-1E88F6BCC07DQ26748343-BCF5814C-25F1-4CA7-A777-95E00E2C8CFCQ26764882-55491A02-C1EF-4875-A4DB-42BC79D1D228Q26765299-3D173637-E3AB-43F7-A382-A32488602B2CQ26766303-AAD3F198-582A-4713-B3CB-F6DF1E9881D4Q26771544-19996C09-4FDB-4B4B-AD29-376455AA9A7FQ26771864-C080C87B-BD86-4DBD-AFDF-0C539071C1CAQ26784125-B1B7AFC9-6020-4C20-B82A-5848FECD5FBCQ26799710-F9A9201E-151C-4E67-9FDF-D9E5F739EB74Q26801895-7A02A7D0-B850-439C-A6F3-FA30D9946B33Q26828439-241EEEF5-009C-4EDD-B6D3-A490AB7BD2BBQ26863536-85510448-4D82-449F-9380-C418CDDD829DQ26863548-589C9FA7-2339-4B0D-9BBE-F3FF24422A05Q27003866-15548292-D6C3-4423-BD54-15657C0F7613Q27016072-1E4078F7-14A3-4FF5-9908-7AB87CBD6B4CQ27339343-5D213BB8-289F-4E08-A43C-EB83775A4A5DQ28066141-4305D113-7768-4171-907B-BB6CCB71ECE8Q28066262-C3BB21F8-E76A-4C8F-9896-EB7A77A36FBDQ28070346-DC51D84F-5A2A-4C89-821C-014D28F4CEE0Q28076171-DB9EE255-4232-44C7-B924-4BC1F53221B2Q28081918-0EAA082C-1EC1-4EF6-86F6-20A3AB7E3002Q28256340-3D5F8EED-E0B3-4D3C-BF11-1427D4AFB4BEQ30491580-D4C35488-6B5E-4237-A6DA-397618F59789Q32179630-5D05216A-D295-4508-82E4-12F6C52855A4Q33430766-3AA4E1F6-0F19-46FF-AC86-A8B84B921E73Q33617298-641560F4-BD58-489C-B0C2-7073A5BAA842Q33692054-7E15DCC7-1768-4F6A-9A07-E2720B1405E0Q33750215-2E714080-0B47-410B-8292-5A2B5A5F2AA7Q33847039-A4999460-C263-4DF4-9344-A48653AB6EA6Q34047821-02CF1CD6-A701-4BCB-B6EE-9810A22DAAD0Q34099930-755E7279-4E57-4383-B968-925F93D1AE1FQ34111320-6D1FF34E-71C4-4EAA-AF5A-562EB3F0ED8CQ34312531-64F94552-B6E4-4622-9237-249D80514C8FQ34419638-E7D2B3D9-0D7A-4836-ACC6-F4854B88AC3FQ34469002-E79E5496-4171-4741-BDC0-215DFB1C7054Q34497406-65E29FE8-E3B1-453B-81AA-05685AE305F7Q34571082-779B6A1A-43D8-479B-A357-01BA0758B758Q34672800-0370D75D-0800-4C15-A7DD-60DE30E04926Q34688742-4BC2F2C7-CE41-4FFE-A452-254ABF9CF0BDQ34725585-8B3E927B-81BB-4573-BBBB-DC8E27A24137
P2860
A specific antidote for dabigatran: functional and structural characterization
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
A specific antidote for dabigatran: functional and structural characterization
@ast
A specific antidote for dabigatran: functional and structural characterization
@en
A specific antidote for dabigatran: functional and structural characterization
@nl
type
label
A specific antidote for dabigatran: functional and structural characterization
@ast
A specific antidote for dabigatran: functional and structural characterization
@en
A specific antidote for dabigatran: functional and structural characterization
@nl
prefLabel
A specific antidote for dabigatran: functional and structural characterization
@ast
A specific antidote for dabigatran: functional and structural characterization
@en
A specific antidote for dabigatran: functional and structural characterization
@nl
P2093
P921
P3181
P1433
P1476
A specific antidote for dabigatran: functional and structural characterization
@en
P2093
Corey Newsome
Eliud Sepulveda
Herbert Nar
Joanne van Ryn
Keith Canada
Tobias Litzenburger
P304
P3181
P356
10.1182/BLOOD-2012-11-468207
P407
P577
2013-03-08T00:00:00Z